# **Special Issue**

# Recent Advances and Perspectives in the Treatment of Dementia

## Message from the Guest Editors

According to the World Health Organization (WHO), dementia is a syndrome in which deterioration in cognitive function beyond what might be expected from the usual consequences of biological ageing occurs. Dementia affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. Moreover, among patients with dementia, neuropsychiatric symptoms (NPS) are frequently observed. Dementia is a complex disease with multiple etiologies and multiple treatments; however, currently available anti-dementia medicines are disease-modifying therapies and have limited efficacy. Thus, therapy for people diagnosed with dementia with antidementia compounds is still an urgent, unmet need. The journal *Pharmaceuticals* invites both reviews and original articles that shed light on the recent advancements and perspectives in the treatment of dementia. Topics include drug repositioning, multifunctional compounds, the discovery of multitarget-directed ligands (MTDLs), computer-aided drug design, and nonpharmacologic and pharmacologic treatments in clinical trials.

## **Guest Editors**

Dr. Agnieszka Zagórska

Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland

Dr. Anna Czopek

Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland

### Deadline for manuscript submissions

closed (25 May 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



## mdpi.com/si/117025

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

